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Abstract:  Protein-energy  wasting  (PEW)  is  common  in  patients  with  chronic  kidney 
disease (CKD) and is associated with an increased death risk from cardiovascular diseases. 
However,  while  even  minor  renal  dysfunction  is  an  independent  predictor  of  adverse 
cardiovascular prognosis, PEW becomes clinically manifest at an advanced stage, early 
before or during the dialytic stage. Mechanisms causing loss of muscle protein and fat are 
complex and not always associated with anorexia, but are linked to several abnormalities 
that stimulate protein degradation and/or decrease protein synthesis. In addition, data from 
experimental CKD indicate that uremia specifically blunts the regenerative potential in 
skeletal  muscle,  by  acting  on  muscle  stem  cells.  In  this  discussion  recent  findings 
regarding the mechanisms responsible for malnutrition and the increase in cardiovascular 
risk in CKD patients are discussed. During the course of CKD, the loss of kidney excretory 
and metabolic functions proceed together with the activation of pathways of endothelial 
damage, inflammation, acidosis, alterations in insulin signaling and anorexia which are 
likely to orchestrate net protein catabolism and the PEW syndrome.  
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1. Protein Energy Wasting (PEW) in CKD: Clinical Implications 
In spite of the advancements in current techniques of renal replacement therapy, mortality levels 
remain high in patients with CKD [1. This increase in mortality is not only limited to dialysis patients, 
but includes the whole ranges of GFR during the progression of CKD [2,3 and is mainly due to 
cardiovascular disease (CVD) and, at advanced stages, to infections [4. The prevalence of protein 
energy wasting (PEW), a condition of loss of muscle and visceral protein stores not entirely accounted 
for  by  inadequate nutrient  intake [5 increases progressively along with the loss of residual renal 
function and is high in dialysis patients [5.  
Uremia-induced alterations in protein metabolism and gastrointestinal tract function can result in 
poor nutritional status, which in turn increases the risks of CVD and infection. The classical risk 
factors  for  CVD  (such  as  old  age,  lifestyle,  smoking,  hypertension,  dyslipidemia,  diabetes,  left 
ventricular hypertrophy, hearth failure) are over-expressed in CKD patients, partly because of the 
clinical characteristics of the CKD population (which consists mainly of old subjects, with many of 
them affected by CVD and type II diabetes) [6. However, the excess of cardiovascular risk related to 
CKD may be due in part to a higher prevalence of non-traditional risk factors peculiar to CKD which 
per se may promote endothelial dysfunction and/or atherogenesis [1. 
An example of the relevance of non-traditional risk factors is offered by the phenomenon of the 
“reverse epidemiology” in dialysis patients [7. While in the general population a high body mass 
index (BMI; Kg/m
2) is associated with an increased cardiovascular risk and with all-cause mortality, in 
dialysis patients the effect of overweight or obesity is paradoxically
 in the opposite direction, with a 
higher BMI leading to an improved survival [7. The “reverse epidemiology” phenomenon involves 
also  several  other  traditional  risk  factors,  such  as  blood  pressure  and  serum  concentrations  of 
cholesterol, homocysteine, and creatinine [8. In addition, during the course of progressive decline in 
renal function, the profile of risk for death may change because the occurrence of others risk factors, 
such as progressive wasting [9], and inflammation [10], which may play an increasing role and may 
outweigh  the  effects  of  traditional  risk  factors.  Chmielewski  et  al.  [11]  recently  showed  that 
apoB/apoA-I ratio is associated with greater survival in hemodialysis (HD) patients only in the short 
term (1-year mortality).Similar data were obtained in another study [12], where the reverse association 
between hypercholesterolaemia and all-cause mortality declined gradually after the first year of follow 
up. This is probably due to the temporal impact of competing risks.  
Liu et al. [13 recently postulated that the paradoxical relationship between cholesterol level and 
mortality could be explained by the effect of the presence of the complex malnutrition-inflammation 
(defined as BMI < 23 kg/m
2 or C-reactive protein > 10 mg/L) in the dialysis population. Recently, 
Contreras et al. [14] assessed the prevalence of malnutrition-inflammation and its modifying effects on 
the  risk-relationship  of  cholesterol  levels  with  subsequent  CVD  events  in  African  American  with 
hypertensive CKD. They showed that the hazard ratio for the primary CVD outcome increased as total 




subjects with malnutrition-inflammation. It should be considered that the phenomenon of “reverse 
epidemiology” is not exclusive of renal patients, but is also observed in sarcopenia of aging [15] and in 
chronically  wasted  patient  groups  affected  by  chronic  heart  failure,  HIV  infection  or  cancer  [16] 
suggesting  that  the  effects  of  wasting  may  overcome  those  of  traditional  risk  factors  for  
cardiovascular disease.  
The aim of this work is to review the mechanisms responsible for PEW, while providing a summary 
of the non-traditional factors which increase the cardiovascular risk in CKD patients. The mechanisms 
underlying the causes of the wasting syndrome are beginning to be understood and include the loss of 
kidney  metabolism  and  function  as  well  as  the  activation  of  pathways  of  endothelial  damage, 
inflammation, acidosis, altered intracellular IGF-1 and insulin signaling. These factors overlap with 
those already operating in ageing and in comorbid conditions, such diabetes and sepsis, and are likely 
to orchestrate the PEW syndrome.  
2. Biomarkers/Proxies for Malnutrition and Mortality in CKD 
Several  biomarkers  have  been  associated  with  worse  outcomes  in  CKD  and  dialysis  patients. 
Among  these,  those  of  PEW  appear  to  be  the  strongest  predictor  of  survival  [9].  Lower  serum 
albumin [17,  prealbumin  [18,  cholesterol  [13,  serum  transferrin  [18,  creatinine  [19  and 
bicarbonate [20 levels are associated with mortality in dialysis patients. Other biochemical markers 
that  are  directly  or  indirectly  linked  to  PEW  and  outcomes  include  various  hormones  such  as 
testosterone [21,  leptin  [22,  visfatin  [23,  adiponectin  [22  and  thyroid  hormones  [24,25.  The 
mechanisms of action responsible for the adverse outcomes associated with PEW markers remain 
unclear:  it  is  likely  that  a  combination  of  factors  are  responsible,  rather  than  a  single  etiologic 
mechanism [9. 
2.1. Hypoalbuminemia 
Hypoalbuminemia is the most commonly used surrogate of PEW in dialysis patients and has a 
strong association with increased mortality [17 and morbidity [26. Hypoalbuminemia is associated 
with development of de novo and recurrent cardiac failure in HD and CAPD patients [27. The use of 
serum  prealbumin  has  been  advocated  as  a  better  surrogate  of  nutritional  status  than  albumin  in 
dialysis patients [28. A confounding factor is that serum albumin and prealbumin are also negative 
acute  phase  reactants  and  their  serum  levels  are  profoundly  affected  by  the  presence  of  an 
inflammatory response. It is already known from studies in 1940s (the “Minnesota Experiment”), that 
albumin levels are extraordinarily preserved, while fat an muscle mass is lost, when nutrient intake is 
curtailed [29. Also CKD patients compliant with a restricted protein and energy intake do not show a 
remarkable decrease of serum albumin levels [30,31. In dialysis patients, hypoalbuminemia could also 
be favoured by the loss of amino acids and/or protein during renal replacement therapy [32. Therefore, 
it  is  not  clear  whether  the  negative  clinical  outcome  in  advanced  CKD  patients  associated  with 
hypoalbuminemia is a reflection of nutrition or of the inflammatory response or both. It is also not 
clear whether the relationship between hypoalbuminemia and increased mortality in dialysis patients 
stems from the intrinsic effects of albumin, or hyopoalbuminemia represents the occurrence of ongoing 




states [33, and increased blood viscosity [34. Moreover, low oncotic pressure may adversely affect 
water shift between the intravascular and interstitial space. Albumin also has important roles as a 
scavenger of free radicals, is a binding agent for toxic compounds and a carrier for a wide variety of 
drugs and hormones [35. Reduced albumin binding of drugs and endogenous ligands is a feature of 
uremia [36. 
 
2.2. Oxidative Stress 
Oxidative stress results from an imbalance between oxidant generation and anti-oxidant defense 
mechanisms,  leading  to  cell  and  tissue  injury.  It  is  consistently  accepted  that  in  CKD  patients  a 
deficiency  in  the  antioxidant  systems  combines  with  an  increase  in  pro-oxidant  activity  owing  to 
advanced  age,  diabetes,  chronic  inflammation,  sepsis  and  the  bio-incompatibility  of  dialysis 
membranes and solutions. Nguyen-Khoa et al. [37 found a direct correlation between lipid and protein 
oxidation markers and CRP levels; in addition, plasma alpha-tocopherol resulted inversely correlated 
with CRP levels and with the duration of dialytic treatment [37. The accumulation of AGEs observed 
in CKD could be partly due to a reduced renal clearance of these compounds, but also to an increased 
de novo generation, stimulated by oxidative stress and inflammation. AGEs could play an important 
role in the development of atherosclerosis, by stimulating the activation of mononuclear cells (thus 
inducing endothelial dysfunction) and also by modifying LDLs, which become less able to be cleared 
by the LDL receptors [38. Moreover, the interaction between AGEs and their receptors (RAGEs), 
could lead to the generation of intracellular oxidative stress and inflammatory mediators through the 
NF-kB pathway [39. These mechanisms could explain the role of AGEs in the high frequency of CVD 
and increased all-cause mortality. Nakashima et al. [40 found that both sRAGE and the RAGE ligand 
S100A12 are elevated in CKD patients. However, while a direct correlation was observed between 
S100A12 and CRP, IL-6 and cardiovascular mortality, sRAGE resulted negatively associated with 
CRP and didn’t predict mortality. 
Advanced oxidation protein products (AOPPs) are a class of dityrosine-containing protein products, 
which arise from the reaction between chlorinated oxidants and plasma proteins. AOPPs could play a 
role  in  the  progression  of  CKD,  since  they  induce  podocyte  apoptosis  through  the  activation  of 
NADPH-oxidase  [41.  In  addition,  AOPPs  can  trigger  the  phagocyte  nicotinamide  adenine 
dinucleotide  phosphate  (NADPH)  oxidase  and  myeloperoxidase  (MPO)-dependent  activities  [42.  
Descamps-Latscha et al. [43 found a direct correlation between CRP, fibrinogen, AOPP levels and 
incident first occlusive atherosclerotic cardiovascular events in CKD patients. Some possible errors in 
the determination of AOPPs in plasma derive from their UV detection since triglycerides and other 
particles  determining  turbidity  may  interfere  in  their  quantitation  and  cause  their  overestimation.  
Valli  et  al.  [44  showed  a  strong  correlation  between  triglycerides  and  AOPPs  not  only  in  CKD 
patients, but also in healthy controls.  
2.3. Microinflammation 
Several visceral proteins and hormones which decrease in blood in response to malnutrition (such 
as albumin, prealbumin, transferrin, retinol binding protein and IGF-I) are also negative acute-phase 




significant  percentage  of  chronic  hemo-  and  peritoneal  dialysis  patients  have  increased  levels  of  
pro-inflammatory cytokines (IL-1, IL-6, TNF alpha) suggesting that a systemic inflammatory response 
is  common  in  dialysis-treated  patients  [45,46].  Moreover,  cross-sectional  studies  suggest  that 
inflammation is responsible for serologic and anthropometric evidence of malnutrition [46]. Elevated 
CRP  is  strongly  associated  with  cardiovascular  mortality  [47],  so  that  the  association  between 
inflammation and atherosclerosis seems to be particularly strong in dialysis patients. Although precise 
mechanisms that contribute to the high prevalence of inflammation in CKD are unknown, ROS have 
been proposed as a potential contributor. On one hand, oxidative stress is able to activate transcriptor 
factors, such as NF-kB, which regulate inflammatory mediator gene expression. On the other hand, 
chronic  inflammation  may  cause  increased  oxidative  stress,  thus  creating  a  vicious  circle  in  the 
determination of cardiovascular risk in CKD patients. 
Notably, CRP and IL-6 levels increase progressively along with the decline of glomerular filtration 
rate in CKD patients [45,48]. These effects could be due to reduced kidney excretory function, since at 
least some pro-inflammatory cytokines are excreted through the kidney. In addition, haemodialysis 
may activate an inflammatory cascade, because of the exposure of blood to bioincompatible dialysis 
membranes and/or backfiltration of lipopolysaccharide through the dialysis membranes [49].  
Pro-inflammatory  cytokines  may  cause  anorexia,  induce  resistance  to  GH  and  IGF-I  [50]  and 
increase energy expenditure [51]. CRP per se may induce vascular damage, since CRP formed locally  
in  the  kidney  reduces  nitric  oxide  production  and  induces  monocyte  recruitment  and  foam  cell  
formation [52].  
New inflammatory markers are coming into play. Pentraxin-3 (PTX3), an inflammatory mediator 
structurally linked to CRP produced by vascular endothelial cells and macrophages in response to  
pro-inflammatory signals, has been shown to be elevated in haemodialysis patients [53], and has been 
identified as a novel mortality risk factor in incident dialysis patients and CKD patients, independent 
of traditional risk factors, CRP and flow-mediated dilation [54,55]. Of interest, fat also seems to be a 
significative source of PTX3 [56]. 
Another recently identified biomarker of inflammation in CKD patients is CD14. This molecule is a 
pattern-recognition receptor that plays a central immunomodulatory role in pro-inflammatory signaling 
in  response  to  a  variety  of  ligands,  including  endotoxin.  CD14  protein  is  present  both in soluble 
(sCD14) and membrane-bound forms. Raj et al. [57] showed an association between sCD14 levels and 
the presence of PEW in hemodialysis patients, probably due to cytokine activation.  
3. Effect of Body Composition on the Risk of Mortality of CKD Patients 
The protective effect of large body size in dialysis patients may be associated with higher adipose 
tissue and fat reserves. This appears to be somewhat contradictory, since adipose tissue, especially 
visceral fat, has pro-inflammatory properties. As an alternative explanation, the “protective” effect  
of BMI might be related to fat-free mass. Even though fat tissue is related to inflammation in the  
general  population,  in  dialysis  patients  it  may  be  associated  with  relatively  greater  secretion  of  
anti-inflammatory cytokines, such as adiponectin, than pro-inflammatory molecules [58]. There is no 
difference  in  plasma  inflammatory  markers  (IL-6,  TNF-α,  and  CRP)  in  individuals  with  different 




fatty  mass  (FM)  and  lean  body  mass  (LBM)  to  clinical  outcomes  in  CKD  patients  who  undergo 
maintenance haemodialysis [60,61]. Some of these studies have suggested that the protective effect of 
high BMI against mortality is related to higher FM [62].  
Recent findings suggest that the type and the distribution of fat rather than its total amount play a 
role in the determination of risk [63]. Particularly, abdominal fat accumulation is a mortality risk factor, 
since it is a source of pro-inflammatory adipokines [64]. Both leptin and visfatin seem to play a role in 
CVD and endothelial dysfunction [65,66] and the receptors of these adipokines are highly expressed in 
atherosclerotic plaques [67,68]. Ramkumar et al. [69] however, suggested that the protective effect of 
BMI in the maintenance haemodialysis population is mostly conferred to those patients with a higher 
LBM (muscle mass), estimated by urine creatinine content. Huang et al. [70] recently reported that low 
mid-arm muscle circumference (MAMC), a surrogate of LBM, and low triceps-skinfold thickness, an 
indicator  of  FM,  were  each  associated  with  higher  all-cause  mortality  in  haemodialysis  patients. 
Higher FM in both sexes and higher LBM in women appear to confer a protective effect. However, the 
survival advantage of FM appears to be superior to that of LBM [71]. 
4. Mechanisms of PEW 
4.1. Altered Amino Acid and Protein Handling by the Diseased Kidney 
The human kidney plays a major role in the homeostasis of body amino acid pools. The kidney is 
the major organ for the disposal of glutamine and proline from the arterial blood, and for the net 
release of some amino acids such as serine, tyrosine and arginine, which are newly generated within 
the kidney for export to other tissues [72,73]. The magnitude of the net release or uptake of amino 
acids by the normal kidney can be understood if one considers that in a 70 Kg man the daily net 
production of serine is ~3–4 g, that of tyrosine ~1 g, that of arginine ~2 grams. In addition the human 
kidney plays also a major role in the removal of glutathione [74], and of S-adenosylhomocysteine 
(SAH) [75]. Besides that, the kidney also releases smaller amounts (<1 g/day) of threonine, lysine and 
leucine into the systemic circulation [72].  
The  human  kidney  plays  also  a major  role in whole body protein metabolism and amino  acid 
oxidation  [76,77]  as  well  as  in  the  regulation  of  plasma  levels  of  several  hormones  and  peptide 
compounds  (i.e.,  prostaglandins,  thyroid  hormone,  parathyroid  hormone,  insulin,  growth  hormone 
(GH),  1,25  dihydrocholecalciferon),  whose  concentrations  and  effects  result  therefore  altered  in  
renal failure.  
4.2. The Kidney and Methionine Transmethylation  
The  biological  effects  of  methionine  transmethylation,  by  which  the  methyl  group  of  
S-Adenosylmethionine (SAM) is donated to a large variety of acceptor substrates, is needed for the 
synthesis of a wide range of compounds such as membrane phospholipids, neurotransmitters, proteins, 
creatine and hormones [76]. Methylation processes play also a major role in the epigenetic regulation 
of protein expression and changes in human DNA methylation patterns are an important feature of 
many  diseases,  including  atherosclerosis  and  cancer  [78].  S-adenosylhomocysteine  (SAH)  is  the  
by-product of methionine transmethylation and the precursor




feedback inhibitor of most methyltransferases, including the methionine remethylation pathway, this 
compound plays an essential role in the control of the overall transmethylation rates [76]. Thus, the 
efficiency of methyltransferase reactions is dependent on efficient tissue removal of SAH [79]. Recent 
experimental [80] and clinical evidence [81] also suggests that the accumulation of SAH in body fluids, 
rather  than  increased  homocysteine  levels,  is  associated  with  vascular  disease  and  tissue  damage. 
Posttranslational modification of proteins, associated with high SAH intracellular accumulation, has 
been  described  in  patients  with  CKD  [82].  To  explore  the  sites  and  mechanisms  underlying  the 
regulation of circulating SAH levels, we measured plasma SAH across the kidney, splanchnic bed and 
lung in humans [75]. Our results showed that the human kidney plays a unique role in the removal of 
SAH from the circulation, indicating that the kidney may have an important role in the control of body 
transmethylation reactions.  
4.3. The Kidney and Nitric Oxide (NO) Synthesis 
In the endothelium, a central regulatory reaction is the generation of NO from L-arginine, which is 
controlled by NO synthase. It is of note that the NO production is decreased in CKD patients [83]. 
There  are  many  causes  to  explain  the  NO  deficiency.  One  obvious  cause  is that limited  arginine 
provision by diseased kidney hinders tissue availability of this amino acid. However, a decrease in 
arginine levels is rarely observed in CKD patients suggesting the existence of sources of arginine other 
than the kidney [76]. In patients with advanced renal disease, anorexia could blunt nutritional intake, 
thus further curtailing tissue arginine pools. NO deficiency could be induced by increased reactive 
oxygen species (ROS) generation and by decreased tetrahydrobiopterin (BH4), an important cofactor 
for  NOS  [84].  In  addition,  the  accumulation  in  blood  fluids  of  NO  Synthase  inhibitors,  such  as 
asymmetric  dimethilarginine  (ADMA)  could  explain  the  strong  association  between  ADMA  and 
carotid  atherosclerosis  as  wall  as  with  overall  and  cardiovascular  mortality  [85].  Initially,  it  was 
assumed that the increased plasma ADMA in ESRD reflected loss of renal clearance [86]. However, 
very little ADMA is excreted unchanged in the urine and the majority is broken down by the enzymes 
dimethylarginine dimethylaminohydrolase 1 and 2 (DDAH1 and 2). DDAH is widely distributed and 
is most abundant in the kidney and also highly expressed in the liver [85]. Decreased metabolism by 
DDAH could be a further cause for ADMA accumulation in CKD patients. ADMA appears to be 
involved  in  CKD  progression,  since  elevated  concentrations  of  ADMA  are  associated  with  the 
development of renal fibrosis in animals [87]. These data suggest that in pathophysiological conditions 
of endothelial dysfunction, the exaggerated endogenous synthesis of ADMA could contribute to CKD 
progression  by  favoring  hypertension  and  extracellular  matrix  synthesis.  Short-term  reduction  of 
circulating  ADMA  by  hemodialysis  is  associated  with  amelioration  of  endothelial  dysfunction  in 
patients with ESRD [88].  
4.4. Resistance to GH/IGF-1 
Resistance to GH is responsible for the defective growth of uremic children. Besides its stimulatory 
effects on growth and anabolism, circulating GH and IGF-1 levels may play a role in the metabolic 
response to fasting, by contributing to protein conservation [72]. Growth hormone (GH) resistance is 




muscle wasting. Development of GH resistance in uremia stems from reduced IGF-1 synthesis [89], 
sensitivity [90] or bioavailability [91], but also to impaired GH signal transduction [92]. Defective 
intracellular  GH  signaling  may  stem  from  impaired  GH  stimulated  Jak2-STAT5  phosphorylation, 
which may be the result of inflammation induced SOCS2 expression [92]. In addition, the hepatic 
resistance to GH-induced IGF-1 expression in uremia arises due to defects in STAT5b phosphorylation 
and its impaired binding to DNA, processes further aggravated by inflammation [93]. 
Besides uremia per se, the effectiveness of GH might also be attenuated by other factors often 
found in CKD patients, such as metabolic acidosis [94] and low nutrient intake [95]. We recently  
observed [96] that the GH acute anabolic response regarding two different GH receptor-downstream 
pathways (potassium and amino acid metabolism) is overall preserved in patients with advanced CKD, 
while  it  is  blunted  in  patients  displaying  evidence  of  microinflammation,  suggesting  a  role  for 
inflammatory changes in the regulation of skeletal muscle protein balance.  
4.5. Low Testosterone  
Multiple anabolic signals, which include both an increase in the regenerative potential and protein 
metabolism are activated by androgens. Testosterone stimulates myoblasts and satellite cell proliferation to 
promote repair of muscle damage [97]. In addition, testosterone stimulates muscle protein synthesis [98]. 
Testosterone concentrations decline with aging and chronic disease [99,100] and are correlated to 
worse survival [101,102] and mortality due to cardiovascular disease [103]. Among men treated with 
hemodialysis, testosterone concentrations inversely correlate with all-cause and CVD-related mortality, 
as well as with markers of inflammation, which suggests that hypogonadism may be an additional 
treatable risk factor for patients with CKD [104,105]. 
4.6. Insulin Resistance and Altered Insulin Signaling 
Insulin is a key regulating factor of protein metabolism for the conservation of lean body mass. 
Even small increases in blood insulin levels, well within the physiological range, are associated with 
pronounced suppression of protein breakdown [106]. A post-receptor defect in muscle responsiveness 
to insulin is the cause of insulin resistance with regard to glucose metabolism occurring in CKD  
patients [72]. However, it is not understood whether insulin resistance regarding glucose metabolism 
also extends to the antiproteolytic action of this hormone. If so, it would contribute to the muscle 
wasting which is often found in uremic patients. Bailey et al. recently identified a series of abnormal 
postreceptor signaling changes in the insulin/IGF-1 pathway in muscle of rats with CKD [107]. These 
included  the  occurrence  of  functional  abnormalities  in  the  IRS/PI3-K  cascade  that  decrease  the 
phosphorylation of the downstream effector Akt. The low phosphorylated Akt activity has been shown 
to  stimulate  the  expression  of  specific  E3  ubiquitin  conjugating  enzymes,  atrogin-1/MAFbx  and 
MuRF1,  in  muscle.  Further,  a  decrease  in  muscle  PI3K  activity  could  activate  Bax  leading  to 
stimulation  of  caspase-3  activity  and  increase  protein  degradation  [107].  These defects which are 
specific to uremia can overlap with those due to diabetes in patients with diabetic kidney disease. 
Pupim et al. reported that patients with ESRD secondary to DM have an acceleration of loss of lean 




Metabolic acidosis is a common complication of advanced CKD and may represent another factor 
associated  with  increased  insulin  resistance.  Acidosis  increases  protein  degradation  through  an 
upregulation  of  the  ATP-dependent,  ubiquitin-requiring  pathway  [109].  Correction  of  metabolic 
acidosis with bicarbonate supplementation has been demonstrated to improve insulin resistance in 
animal models of uremia as well as in humans [110]. 
4.7. Anorexia  
Anorexia, together with nausea and vomiting, is one of the signs of uremic intoxication. In addition 
to uremia per se, other possible causes of anorexia in CKD patients include gastroparesis (diabetic 
nephropaty),  depression  and  systemic  disease  (i.e.,  SLE,  congestive  hearth  failure).  Anorexia 
contributes with inflammatory state to the determination of PEW. Moreover, anorexia is associated 
with increased mortality risk in hemodialysis patients [111]. Uremia may cause anorexia through the 
accumulation of toxic molecules, pro-inflammatory cytokines, and middle-size molecules which can 
inhibit appetite. Cheung et al. [112] found that the injection of agouti-related protein (AgRP) in the 
lateral  ventricle  of  mice  with  subtotal  nephrectomy  induced  an  increase  in  food  intake  and  body 
growth,  thus  suggesting  that  uremia  could  cause  a  defect  in  the  capacity  of  AgRP  to  block  the 
melanocortin-4 receptor, MC4-R. Kalantar Zadeh et al. [113] showed an association between anorexia 
and  higher  concentration  of  proinflammatory  cytokines,  hypo-responsiveness  to  erythropoietin, 
hospitalization rates and all-cause mortality in hemodialysis patients. 
Carrero  et  al.  recently  found  a  correlation  between  appetite,  malnutrition,  inflammation  and 
outcome  in  hemodialysis  patients  [114].  Moreover,  they  shown  a  greater  susceptibility  to 
inflammation-induced anorexia in men, as compared to women, in agreement with the recent finding 
in rats of sex specific orexigenic and anorexigenic mechanisms in response to inflammation [115].  
5. Ageing and Protein Metabolism 
In several Western countries, persons over the age 65 are expected to soon become the majority of 
those who will need renal replacement therapy. Nutritional problems are common in elderly patients 
with ESRD and contribute to the debility and morbidity in this group of dialysis patients [116]. Low 
dietary intake and diminished muscle masses are both common in the old individuals and may cause 
low values of BUN and serum creatinine, even in the presence of advanced renal failure [117].  
A decrease in body protein is a major characteristics of ageing [118,119]. It involves mainly muscle 
proteins, and is associated with decreased muscle strenght and functional impairment. Whole body 
protein synthesis and degradation are similar in young and elderly adults, when results are expressed 
per  lean  body  mass  [120,121].  However,  selected  deficits  are  specific  to  certain  muscle  protein 
components,  such  as  myosin  heavy  chain and mitochondrial protein [122]. In addition, in  elderly 
subjects  a  decrease  sensitivity  of  insulin  action  regarding  protein  metabolism  have  been 
described [123].  These  alterations  in  protein  metabolism  due  to  senescence likely potentiate those 
caused  by  uremia.  Weight  loss  in  older  adults  is  highly  predictive  of  increased  morbidity  and 
mortality [124,125]. Several factors contribute to weight loss in older adults. Available data indicate 
that excess cytokine elaboration may be a critical factor in the induction of involuntary weight loss in 




antagonist, and soluble TNF receptor. Acute phase proteins such as C-reactive protein and serum 
amyloid-A are also elevated, which suggests the activation of the entire inflammatory cascade.  
6. Infections  
Chronic uremia is considered a state of acquired immunodeficiency [126] and CKD patients are at 
high risk for infection [127]. Among participants in the HEMO Study [128] who died during follow-up, 
infection  was  the  primary  cause  of  death  in  23%.  The  overall  probability  of  death  during  an  
infection-related  hospitalization  was  15%.  Numerous  factors,  including  advanced  age,  diabetes, 
hypoalbuminemia, immunosuppressive therapy, dialysis catheters, the dialysis procedure and uremia 
per se potentially predispose CKD patients to infections (Figure 1). Malnutrition causes defective 
immune function because of enhanced susceptibility to infections and deficient damage healing [129]. 
There are nutrients such as arginine and glutamine which can improve the immune response [130-132]. 
CKD patients are predisposed to zinc [133,134], vitamin B6 (pyridoxine), vitamin C and folic acid 
deficiencies [135,136], which can lead to alterations in host defense.  
Figure 1. Major mechanisms promoting infections in patients with chronic kidney disease. 
 
The function of polymorphonuclear white blood cells, lymphocytes, and monocytes is altered in 
ESRD  patients  [137-139].  Malnutrition,  increased  intracellular  calcium,  iron  overload,  dialysis 
membranes, and uremic toxins (i.e., circulating factors that inhibit granulocytes) contribute to impaired 
polymorphonuclear leukocyte function [126,138]. In addition, T lymphocyte [140], monocyte, and 
monocyte-derived dendritic cell function is also impaired [141]. Leptin, which accumulates in CKD 
patients, also plays a role in innate and acquired immunity [142,143]. In fact, leptin and its receptor 
share structural similarities with IL-6, IL-11, and IL-12 [144,145]. Leptin regulates T lymphocyte 




macrophages [147]. In addition, leptin induces the expression and secretion of IL-1 receptor antagonist 
(IL-1Ra) by human monocytes [148] as well as the production of TNF and IL-6 [149]. Recent findings 
show  that  leptin  positively  modulates  mononuclear  cell  survival  by  interfering  with  the  apoptotic 
process [150]. More striking, hypoleptinemia characterizing starvation is strictly related to increased 
susceptibility to infection secondary to malnutrition [146,151]. Thus, leptin is now considered as an 
adipokine which is capable of linking metabolism and immune homeostasis [151,152]. In addition has 
been observed that leptin inhibits neutrophil migration in response to classical chemoattractants.  
The serum levels of resistin, a 12-kDa protein expressed in inflammatory cells, are increased in 
patients  with  CKD  and/or  diabetes  [153,154].  These  patients  have  an  increased  risk  of  infections 
because of an impaired polymorphonuclear leukocyte (PMNL) functions. Cohen et al. observed that 
resistin interferes with chemotaxis and oxidative burst of PMNL and that p38 MAPK, ERK (p44/42) 
and PI3K are involved in the regulation of PMNL chemotaxis. Resistin inhibits PNMLs at the high 
concentrations found in serum of uremic patients, but not in concentrations in healthy subjects [155].  
7. A New Perspective: Accelerated Loss of Myonuclei and Defective Regenerative Potential in the 
Skeletal Muscle of CKD Patients  
Decrease  in  nutrient  intake,  metabolic  acidosis,  physical  inactivity,  diabetes,  and  sepsis  are 
conditions associated with CKD which can promote muscle wasting through an increase in protein 
degradation and or a decrease in protein synthesis [156-160]. In addition, the balance between cell loss 
and regeneration can hinder muscle size and function. The role of apoptosis is a new concept in the 
regulation of muscle size and function in physiology and disease [161,162]. During atrophy nuclei are lost 
by apoptosis, while during hypertrophy new nuclei are added to the fibres from muscle stem cells (satellite 
cells) [161,162]. A same signal can theoretically cause cell and protein loss, since Akt can mediate the 
effects of PI3-kinase on different events, such as apoptosis [163-165] and protein catabolism [165]. 
These effects may be especially injurious in uraemia, where impaired Insulin-like Growth Factor I 
(IGF-I) signaling causes abnormal protein metabolism in muscle and decreases the proliferation of 
satellite cells [166]. Zhang et al. observed that transcription factors presents in myonuclei, MyoD and 
myogenin, are reduced in intact and injured muscle of CKD mice. They also found that in satellite 
cells of injured muscle the expression of myogenic factors mRNAs is impaired in CKD, while it is 
stimulated in normal injured muscle [166,167].  
Recently, we analyzed muscle apoptosis and myostatin mRNA and their related intracellular signals 
in rectus abdominis samples obtained from CKD patients scheduled for peritoneal dialysis. Apoptotic 
loss  of  myonuclei  was 3–5 fold increased. In addition myostatin and IL-6 gene expressions were 
enhanced by ~50%, while levels of IGF-I mRNA were lower than in controls. Phosphorylated JNK 
and its downstream effector, p-c-Jun, were upregulated, while p-Akt was markedly downregulated. 
Multivariate analysis models revealed p-Akt and IL-6 to contribute individually and significantly to 
the prediction of apoptosis and myostatin gene expression, respectively. These findings demonstrate 
the occurrence of the activation of multiple pathways to promote muscle atrophy in skeletal muscle of 
CKD patients. Both apoptosis of myonuclei and myostatin are upregulated. However, they appear to 
be  associated  with  different  signals,  suggesting  that  their  intracellular  pathways  are  differently 




Changes in muscle metabolism of specific amino acids induced by uremia could impair muscle 
regeneration. In patients with CKD, a reduced release of valine and leucine from muscle is likely 
responsible for their reduced levels in blood [169]. It has been supposed that an increased muscle 
degradation of valine, probably due to metabolic acidosis [165] and /or an impaired glucose utilization, 
accounts for the low release of this amino acid from peripheral tissues. Studies in rats and humans with 
CKD indicate that the correction of metabolic acidosis raises both plasma and muscle BCAA levels by 
decreasing the transamination and decarboxylation in muscle [170,171]. During the course of CKD, 
abnormalities due to decreased nutrient intake overlap those caused by acidosis, and the declining 
plasma  valine  levels  have  been  reported  as  an  index  of  poor  nutrition  and  reduced  lean  body 
mass [172]. It is of note that leucine cooperates with IGF-1 in stimulating the activation of myogenic 
satellite  cells.  These  cells  are  responsible  for  muscle  regeneration  in  different  situations,  such  as 
damage-induced  muscle  loss,  aging  and  progressive  neuromuscular  diseases.  The  leucine-induced 
activation of satellite cells is obtained through the mammalian target of rapamycin (mTOR) signaling, 
one of the main pathways responsible for protein synthesis and cells proliferation. These effects appear 
to  be  due  to  Beta-hydroxy-beta-methilbutyrate  (HMB),  a  leucine  catabolite,  which  may  induce 
myoblasts proliferation, Akt phosphorylation, and prevent muscle wasting in vitro [173].  
In conclusion, PEW is common in patients with CKD and is associated with an increased death risk. 
However, while even minor renal dysfunction is an independent predictor of adverse cardiovascular 
prognosis, PEW becomes clinically manifest at an advanced stage, early before or during the dialytic 
stage. Mechanisms causing loss of muscle protein and fat are complex and not always associated with 
anorexia, but are linked to several abnormalities that stimulate protein degradation and/or decrease 
protein synthesis (Figure 2). In addition, data from experimental CKD indicate that uremia specifically 
blunts the regenerative potential in skeletal muscle, by acting on muscle stem cells. During the course 
of CKD, the loss of kidney excretory and metabolic functions proceeds together with the activation of 
pathways  of  endothelial  damage,  inflammation,  acidosis,  resistance  to  anabolic  hormones,  and 
defective  insulin  signaling.  These  factors  may  overlap  those  already  operating  in  ageing  and  in 
comorbid conditions, such as diabetes and sepsis to orchestrate the PEW syndrome.  
Figure  2.  Scheme  of  major  mechanisms  promoting  PEW  in  patients  with  chronic  
kidney disease.  
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